Issue Date: December 7, 2015
Heptares Adds Two GPCR Partners
Heptares Therapeutics has struck deals with two companies hoping to tap into its G protein-coupled receptor (GPCR) expertise. Heptares and Pfizer will work together to develop drugs targeting up to 10 GPCRs, with the biotech earning up to $189 million per target. Pfizer will also take a stake worth $33 million in Heptares’s parent company, Sosei. Separately, Teva Pharmaceutical Industries will pay $10 million for the rights to Heptares’s small-molecule antagonists of a GPCR protein called CGRP for the treatment of migraines. Teva says the Heptares molecules will complement its TEV-48125, an anti-CGRP antibody.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society